Current position

Cathie Wood’s Recursion Pharmaceuticals Inc (RXRX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

ARK Investment ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares41.34MHighest verified quarter-end share count
Quarters reported21Verified quarters with shares above zero
What happened?

ARK Investment Management first reported Recursion Pharmaceuticals Inc in Q2 2021. The reported position was increased and reduced across later filings. ARK Investment Management currently reports 41.34M shares. The latest verified filing showed: Bought 2.8% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 2.8% more+1.12M shares · 41.34M shares reported after the change
Filing context

Quarter-end price $3.67 · Estimated holding basis $8.76

Q1 2026
Bought 7.8% more+2.90M shares · 40.21M shares reported after the change
Filing context

Quarter-end price $3.07 · Estimated holding basis $8.91

Q4 2025
Bought 11.2% more+3.77M shares · 37.32M shares reported after the change
Filing context

Quarter-end price $4.09 · Estimated holding basis $9.36

Q3 2025
Bought 1.7% more+556.87K shares · 33.55M shares reported after the change
Filing context

Quarter-end price $4.88 · Estimated holding basis $9.95

Q2 2025
Sold 5.2% of the position−1.83M shares · 32.99M shares remained
Filing context

Quarter-end price $5.06 · Estimated holding basis $10.04

Q1 2025
Bought 7.6% more+2.47M shares · 34.82M shares reported after the change
Filing context

Quarter-end price $5.29 · Estimated holding basis $10.04

Portfolio importance

How important is Recursion Pharmaceuticals Inc in ARK Investment Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight1.0%Q2 2026
Current rank#31of 190 reported positions
Peak portfolio weight2.0%Q3 2024
Best historical rank#16Q1 2024
At peak importanceQ3 2024
RXRX
2.0%
Largest holding
11.0%
Cross-investor discovery

Who else owns Recursion Pharmaceuticals Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Ray DalioBridgewater Associates, LP
RXRX0.0% of reported portfolio
Explore Recursion Pharmaceuticals Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$3.192026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$3.67Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$8.76Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows ARK Investment Management’s aggregated Form 13F disclosures. It is not Cathie Wood’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.